
Please try another search
On the 15th of September, Orbimed Advisors added 4.8 million Adicet Bio, Inc. (ACET) shares for $77 million at an average price of $15.96 per share. Shares of Adicet Bio, Inc. are down -24.62% since the transaction.
Orbimed Advisors's holding in Adicet Bio, Inc. increased to about 5.5 million shares with the purchase.
Orbimed Advisors first bought Adicet Bio, Inc. stock in the first quarter of 2018. Orbimed Advisors also owns Bristol-Myers Squibb Co (NYSE:BMY), Merck (MRK), Mirati Therapeutics Inc (NASDAQ:MRTX) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX). Adicet Bio, Inc. is its number eleven position by number of shares and market value among biotechnology & life sciences stocks.
In contrast, California State Teachers Retirement System, Millennium Management, and Victory Capital Management sold all their ACET shares.
Orbimed Advisors has also recently reduced their share in Alector, Inc. (NASDAQ:ALEC). The total value of the shares sold is estimated at around $105 million.
In addition, Orbimed Advisors increased their share in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) and TELA Bio, Inc. (NASDAQ:TELA). The total value of the shares bought is estimated at around $2 million.
Orbimed Advisors also reduced their share in ESSA Pharma Inc . (NASDAQ:EPIX) and 89bio, Inc. (NASDAQ:ETNB). The total value of the shares sold is estimated at around $54 million.
Additionally, Orbimed Advisors established new holdings in Fusion Pharmaceuticals Inc. (FUSN). The total value of the shares bought is estimated at around $52 million.
(Reuters) -Dollar General Corp raised its sales forecast for the year on Thursday, as more Americans turn to discount store shopping with inflation at a four-decade high. Shares...
By Senad Karaahmetovic JPMorgan strategist Nikolaos Panigirtzoglou has weighed in on the most recent developments in the cryptocurrency world, notably the collapse of the TerraUSD...
Investing.com - Alibaba (NYSE:BABA) ADR reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations. Alibaba ADR announced...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.